Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Editorial

Central funding for Cochrane Canada must continue

John Fletcher
CMAJ September 22, 2015 187 (13) 947; DOI: https://doi.org/10.1503/cmaj.150830
John Fletcher
Editor-in-Chief,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The Canadian Institutes of Health Research (CIHR) are contemplating withdrawing funding for Cochrane Canada. At this year’s Cochrane Canada Symposium, it was announced that CIHR had given notice that funding would no longer be available to support the centre as of September. This decision would end more than 10 years of central funding for the infrastructure that supports the Cochrane Collaboration in Canada.

The Cochrane Collaboration bears the name of an English epidemiologist who, in 1979, noted that there was more to be gained from collecting together and applying existing medical research than from undertaking further research uninformed by the past.1 This vision caught the imagination of academics in the United States, United Kingdom and Canada. In 1992, under the chairmanship of Canadian Professor David Sackett, the collaboration was formed. Its philosophy: that the task of building a library of systematic reviews and the benefits of this knowledge demanded global collaboration and that no single institution or country should be regarded as the owner. The purpose of the collaboration was to promote a systematic approach to reviewing the medical literature; its emphasis was on comprehensiveness and quality to produce as unbiased a measure of the effectiveness of a drug, operation or intervention with as little statistical uncertainty as possible. The methods for undertaking these reviews were not widely understood at the time. Canadian academics have been responsible for much of the work of cataloguing, teaching and promoting the science of systematic reviews and meta-analysis that underpin current policies of the Canadian Agency for Drugs and Technologies in Health, the Common Drug Review and the Public Health Agency of Canada.

No single institution could have undertaken the 6000 or so reviews now contained in the Cochrane Library — each review has cost about Can$100 000, using local research to contribute to this global effort. Each review is contributed to the library free of charge, but the coordination and quality assurance of the reviews is overseen by review groups and national coordinating centres. Canada is the second largest contributor of reviews (10%), and reaps the benefits of access to 100% of the knowledge generated. Cochrane Canada supports 650 reviews, overseeing 5 review groups in subject areas such as hypertension and musculoskeletal disease, as well as developing methods to reduce bias and promote equity. The UK government supports Cochrane UK with £5.3 million (a little over Can$10 million). The Australian government supports the Australasian Cochrane Centre with $A2 million (Can$2 million), about the same as Canada’s support.

Detractors would say that many of the topics reviewed in the Cochrane Library are not priorities for CIHR, and that reviews are not done quickly enough to provide policy answers to today’s questions. To be fair, the same may be said of much CIHR-funded research. Although reviews of herbal remedies and acupuncture contributed by other countries may not be mainstream, what could be more relevant than the Canadian reviews on hypertension, backache and arthritis? Rapid reviews may give a timely answer, but quality can suffer. Fortunately, tomorrow’s priorities are often anticipated by today’s Cochrane reviews, which can form the basis for future high-quality rapid reviews. Although some may balk at the Cochrane Collaboration entering into a partnership with commercial publisher Wiley–Blackwell, we should not conflate the separate processes of research and publication. Without a publisher, Cochrane reviews could not be widely disseminated. Access to the Cochrane Library is by subscription and has been since the publication of the first edition. Some countries and regions consider the Cochrane Library so valuable that they pay for access for all citizens (e.g., Norway, Western Australia) or all health professionals (e.g., UK). A national licence for Canada would probably cost little more than what is already paid by Canadians and Canadian institutions.

The Canadian Institutes of Health Research may regard spending on infrastructure as detracting from its ability to fund new research directly, but both are needed. Part of CIHR’s mandate is to “excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians.”2 Creating and translating knowledge into practice requires organization. As Archie Cochrane noted:

It is surely a great criticism of our profession that we have not organized a critical summary, by specialty or subspecialty, adapted periodically, of all relevant randomized control trials.

Cochrane Canada exemplifies this organized effort of international scientific excellence, creating new knowledge and translating it into Canadian practice. What better use could there be of Can$2 million — 0.2% of CIHR’s budget?

Canada showed leadership when it helped found the Cochrane Collaboration. It would be better for this leadership to continue through CIHR’s support of universal access to Cochrane’s valuable body of knowledge than for Canada to be the first founding member to withdraw central funding.

Footnotes

  • Competing interests: See www.cmaj.ca/site/misc/cmaj_staff.xhtml

References

  1. ↵
    1. Cochrane AL
    . 1931–1971: a critical review with particular reference to the medical profession. In: Teeling-Smith G, Wells N, editors. Medicines for the year 2000. London: Office of Health Economics; 1979:1–11.
  2. ↵
    Our mandate. Ottawa: The Canadian Institutes of Health Research; 2013. Available: www.cihr-irsc.gc.ca/e/7263.html (accessed 2015 July 15).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 187 (13)
CMAJ
Vol. 187, Issue 13
22 Sep 2015
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Central funding for Cochrane Canada must continue
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Central funding for Cochrane Canada must continue
John Fletcher
CMAJ Sep 2015, 187 (13) 947; DOI: 10.1503/cmaj.150830

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Central funding for Cochrane Canada must continue
John Fletcher
CMAJ Sep 2015, 187 (13) 947; DOI: 10.1503/cmaj.150830
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A letter to our colleague, Canadas new Minister of Health
  • Google Scholar

More in this TOC Section

  • Accroître le rayonnement du JAMC
  • Extending the impact of CMAJ
  • La vaccination contre le SRAS-CoV-2 devrait être obligatoire pour exercer la médecine au Canada
Show more Editorial

Similar Articles

Collections

  • Areas of Focus
    • Health services
  • Topics
    • Journalology & publication ethics
    • Research methods & statistics

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire